NCT01027013View on ClinicalTrials.gov

Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Patients With Dry Eye

PHASE2CompletedINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

October 31, 2010

Study Completion Date

November 30, 2010

Conditions
Dry Eye SyndromesKeratoconjunctivitis Sicca
Interventions
DRUG

rebamipide 2% ophthalmic suspension

Instill one drop in each eye four times daily for 12 weeks.

DRUG

placebo eye drops

Instill one drop in each eye four times daily for 12 weeks.

Trial Locations (5)

38119

Total Eye Care, P.A., Memphis

40205

Richard Eiferman, MD, Louisville

06708

The Eye Care Group, P.C., Waterbury

04240

Central Maine Eye Care, Lewiston

01810

Ora, Inc, Andover

Sponsors

Lead Sponsor

Kubota Vision Inc.
All Listed Sponsors
collaborator

Otsuka Pharmaceutical Co., Ltd.

INDUSTRY

lead

Kubota Vision Inc.

INDUSTRY

NCT01027013 - Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Patients With Dry Eye | Biotech Hunter | Biotech Hunter